Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Accounts Payable 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -29.90%

Aerovate Therapeutics Inc Accounts Payable 1 year YoY Change (%) is -29.90% for the Trailing 12 Months (TTM) ending March 31, 2024, a -145.95% change year over year. Accounts Payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Aerovate Therapeutics Inc Accounts Payable for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 4.73 M, a 65.07% change year over year.
  • Aerovate Therapeutics Inc Accounts Payable for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 2.86 M, a 84.71% change year over year.
  • Aerovate Therapeutics Inc Accounts Payable for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.55 M.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email